Ribo is a biotechnology company specializing in the development of RNA interference (RNAi) therapeutics. The company operates in the biopharmaceutical sector, focusing on creating innovative treatments that target and silence specific mRNA molecules to halt the production of disease-causing proteins. Ribo's core technology involves oligonucleotide molecules that bind to target mRNA, either triggering its degradation or blocking its translation, thereby preventing the expression of harmful proteins.

Ribo serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The company operates primarily in the Asian market but has a global reach through strategic partnerships and licensing agreements. Ribo's business model is based on a vertically integrated oligonucleotide therapeutic platform that supports the entire lifecycle of RNAi therapeutics, from early-stage research and development (R&D) to commercialization.

The company generates revenue through various channels, including licensing its intellectual property, forming strategic partnerships, and commercializing its RNAi-based products. Ribo has built a significant portfolio of patents and proprietary technologies, which are recognized as industry-leading innovations in RNAi therapeutics.

In summary, Ribo is committed to advancing its RNAi technologies and bringing best-in-class and first-in-class RNAi therapeutics to the market. The company's liver-targeting delivery technology and second-generation modification chemistry have already supported several products entering clinical development phases.

Keywords: RNAi therapeutics, oligonucleotide, mRNA silencing, biopharmaceutical, liver-targeting, clinical development, intellectual property, strategic partnerships, commercialization, innovation.